Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novartis -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (172)	2/11/1998 12:07:00 PM
From: Tom Wilkes	Read Replies (1) \| Respond to of 296

I'm still high on Novartis for the long haul, Henry. My last posting doesn't seem to be here, so I am posting again. Novartis was recently profiled in Forbes (whose profiles have given me great advice in the past); one of their arguments is that, unlike most pharmaceutical firms, Novartis has many new drugs whose patents do not expire for a long time. Also, their sales figures for the past year were phenomenal. Sales drive earnings, right? Any thoughts about the long term from a biotech perspective? Tom Wilkes